Clinical experience with Cerebrolysin.
Cerebrolysin is a peptidergic drug which displays neurotrophic action in various animal models. It is used for the treatment of dementia and in this report we provide evidence for the long-term clinical efficacy of Cerebrolysin in Alzheimer's disease. This evidence is based on our clinical experience with Cerebrolysin, stemming from our participation in a double-blind, placebo-controlled clinical trial, a compassionate use programme initiated thereafter, and a PET study. Our data suggests, that Cerebrolysin is a safe and effective treatment for Alzheimer's disease and that repeat treatments may maintain function in patients over the long-term.
Molloy
D W
DW
Geriatric Research Group, McMaster University Department of Medicine, Hamilton, Ontario, Canada.
Standish
T I
TI
D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000523:psychology; D000596:Amino Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000378:metabolism; D003071:Cognition / Q000187:drug effects; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012016:Reference Values; D014055:Tomography, Emission-Computed
D000596:Amino Acids; D018697:Nootropic Agents; C006952:cerebrolysin